{"entity":{"id":"itr-251","kind":"drug","name":"ITR-251","aka":[],"tldr":"ITR-251 is an experimental small molecule from Iteria Biopharma, in phase 1 trials for metastatic castration-resistant prostate cancer and advanced solid tumours.","summary":"ITR-251 is a small molecule from Iteria Biopharma. A potent and selective, reversible inhibitor of monoamine oxidase A (MAO-A) with limited capacity to cross the blood-brain barrier. Its furthest stage is phase 1, for metastatic castration-resistant prostate cancer and advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1/1b NCT07870096 is registered but NOT YET RECRUITING; first in advanced solid tumours, then with androgen receptor pathway inhibitors and ADT in metastatic castration-resistant prostate cancer. If the writer prefers stage to mean dosed patients, use preclinical. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Iteria Biopharma: iteriabiopharma.com","url":"https://iteriabiopharma.com/pipeline/"},{"label":"Iteria Biopharma: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07870096"},{"label":"ClinicalTrials.gov: trials of ITR-251","url":"https://clinicaltrials.gov/search?intr=ITR-251"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc","metastatic-cancer"],"sections":[],"technologies":[],"targets":["maoa"],"drugs":[],"companies":["iteria-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07870096"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ITR-251","modality":"Small molecule","mechanism":"A potent and selective, reversible inhibitor of monoamine oxidase A (MAO-A) with limited capacity to cross the blood-brain barrier.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/itr-251/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"target":[{"id":"maoa","kind":"target","name":"MAO-A (MAOA)","route":"/targets/maoa/"}],"company":[{"id":"iteria-biopharma","kind":"company","name":"Iteria Biopharma","route":"/companies/iteria-biopharma/"}],"trial":[{"id":"nct07870096","kind":"trial","name":"ITR-251 in Patients With Advanced Solid Tumors","route":"/trials/nct07870096/"}]}}